董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary Sender | 男 | Director | 58 | 未披露 | 未持股 | 2020-08-18 |
| John C. Jacobs | 男 | President and Chief Executive Officer, Director | 53 | 84.57万美元 | 未持股 | 2020-08-18 |
| Antonio Gracias | 男 | Director | 49 | 未披露 | 未持股 | 2020-08-18 |
| Jack Bech Nielsen | 男 | Director | 56 | 未披露 | 未持股 | 2020-08-18 |
| Juan A. Sabater | 男 | Director | 56 | 未披露 | 未持股 | 2020-08-18 |
| Andreas Wicki | 男 | Director | 61 | 未披露 | 未持股 | 2020-08-18 |
| Jeffrey S. Aronin | 男 | Director, Chairman | 52 | 未披露 | 未持股 | 2020-08-18 |
| Jack B. Nielsen | 男 | Director | 56 | 未披露 | 未持股 | 2020-08-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John C. Jacobs | 男 | President and Chief Executive Officer, Director | 53 | 84.57万美元 | 未持股 | 2020-08-18 |
| Susan L. Drexler | 女 | Chief Financial Officer | 51 | 未披露 | 未持股 | 2020-08-18 |
| Jeffrey Dayno | 男 | Chief Medical Officer | 63 | 67.22万美元 | 未持股 | 2020-08-18 |
| Jeffrey Dierks | 男 | Chief Commercial Officer | 49 | 未披露 | 未持股 | 2020-08-18 |
| Andrew Serafin | 男 | Chief Business Officer | 46 | 53.70万美元 | 未持股 | 2020-08-18 |
董事简历
中英对照 | 中文 | 英文- Gary Sender
-
Gary Sender于2020年10月被任命为董事会成员，目前担任董事会审计委员会主席和薪酬委员会成员。Sender先生是一位高级执行官和董事会成员，在大型，跨国制药和早期生物技术公司拥有超过25年的财务领导经验。他曾担任Nabriva Therapeutics plc（Nasdaq:NBRV）的首席财务官，该公司是一家商业阶段的上市生物制药公司，自2016年5月起从事创新抗感染药物的商业化和开发，以治疗严重感染。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任Synergy PharmaceuticalsInc.执行Vice President兼首席财务官。此前，从2009年8月到2015年6月，森德还担任过Shire plc的财务高级副总裁，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生从2004年8月到2009年7月担任再生医学公司Tengion，Inc.的首席财务官。Sender先生还在默克公司（Merck&Co.）担任了15年多的领导职务。Inc.，一家制药公司。Sender先生目前在Harmony Biosciences（NASDAQ:HRMY）的董事会任职，并担任其审计委员会主席，并且是其薪酬委员会的成员，也在Schr&246；Dinger，Inc（NASDAQ:SDGR）的董事会任职，并担任其审计和薪酬委员会主席。他持有Boston University的财务和信息系统学士学位，以及Carnegie Mellon University的工商管理硕士学位。
Gary Sender,was appointed as a member of Ibio, Inc. Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee of the Board of Directors and as a member of Ibio, Inc. Compensation Committee. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi-national pharmaceutical and early-stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial-stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender currently serves on the board of directors of Schrodinger, Inc. and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences and is the chair of their audit committee and is a member on their compensation committee. Mr. Sender serves on the board of Gennao Bio, a privately held biotechnology firm. He is the chair of both the audit and compensation committees of Gennao. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie-Mellon University. - Gary Sender于2020年10月被任命为董事会成员，目前担任董事会审计委员会主席和薪酬委员会成员。Sender先生是一位高级执行官和董事会成员，在大型，跨国制药和早期生物技术公司拥有超过25年的财务领导经验。他曾担任Nabriva Therapeutics plc（Nasdaq:NBRV）的首席财务官，该公司是一家商业阶段的上市生物制药公司，自2016年5月起从事创新抗感染药物的商业化和开发，以治疗严重感染。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任Synergy PharmaceuticalsInc.执行Vice President兼首席财务官。此前，从2009年8月到2015年6月，森德还担任过Shire plc的财务高级副总裁，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生从2004年8月到2009年7月担任再生医学公司Tengion，Inc.的首席财务官。Sender先生还在默克公司（Merck&Co.）担任了15年多的领导职务。Inc.，一家制药公司。Sender先生目前在Harmony Biosciences（NASDAQ:HRMY）的董事会任职，并担任其审计委员会主席，并且是其薪酬委员会的成员，也在Schr&246；Dinger，Inc（NASDAQ:SDGR）的董事会任职，并担任其审计和薪酬委员会主席。他持有Boston University的财务和信息系统学士学位，以及Carnegie Mellon University的工商管理硕士学位。
- Gary Sender,was appointed as a member of Ibio, Inc. Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee of the Board of Directors and as a member of Ibio, Inc. Compensation Committee. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi-national pharmaceutical and early-stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial-stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender currently serves on the board of directors of Schrodinger, Inc. and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences and is the chair of their audit committee and is a member on their compensation committee. Mr. Sender serves on the board of Gennao Bio, a privately held biotechnology firm. He is the chair of both the audit and compensation committees of Gennao. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie-Mellon University.
- John C. Jacobs
-
John C.Jacobs自2018年6月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。此前，Jacobs先生于2017年10月至2018年6月担任我们的执行Vice President兼首席商务官。在加入我们之前，Jacobs先生于2017年9月至2017年10月担任Teva Pharmaceuticals Industries Ltd.（或Teva，一家上市制药公司）呼吸业务部的高级副总裁兼总经理。他也曾担任Teva公司的商业运营和创新高级副总裁（2016年9月至2017年9月），以及Teva公司的加拿大品牌业务Vice President兼总经理（2014年7月至2016年9月）。Jacobs先生在主要制药公司担任范围越来越广、责任越来越大的职务，其中包括Cephalon Inc.（一家前公共生物制药和生物技术公司）、Wyeth，LLC（一家公共制药公司）和辉瑞公司（一家公共制药和生物技术公司）。Jacobs先生在纽约州立大学普拉茨堡学院（State University of New York College at Plattsburgh）获得商学学士学位，并在纽约州立大学宾厄姆顿分校（State University of New York at Binghamton）获得工商管理硕士学位。
John C. Jacobs has served as our President and Chief Executive Officer and on our board of directors since June 2018. Previously, Mr. Jacobs served as our Executive Vice President and Chief Commercial Officer from October 2017 to June 2018. Prior to joining us, Mr. Jacobs served as the Senior Vice President and General Manager of the Respiratory Business Unit of Teva Pharmaceuticals Industries Ltd., or Teva, a public pharmaceutical company, from September 2017 to October 2017. He also served as Senior Vice President of Commercial Operations and Innovation of Teva, from September 2016 to September 2017 and as Vice President and General Manager of Teva’s Branded Business in Canada from July 2014 to September 2016. Mr. Jacobs has held positions of increasing scope and responsibility at major pharmaceutical companies including Cephalon Inc., a former public biopharmaceutical and biotechnology company, Wyeth, LLC, a public pharmaceutical company, and Pfizer Inc., a public pharmaceutical and biotechnology company. Mr. Jacobs received a B.S. in business from State University of New York College at Plattsburgh and an M.B.A. from The State University of New York at Binghamton. - John C.Jacobs自2018年6月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。此前，Jacobs先生于2017年10月至2018年6月担任我们的执行Vice President兼首席商务官。在加入我们之前，Jacobs先生于2017年9月至2017年10月担任Teva Pharmaceuticals Industries Ltd.（或Teva，一家上市制药公司）呼吸业务部的高级副总裁兼总经理。他也曾担任Teva公司的商业运营和创新高级副总裁（2016年9月至2017年9月），以及Teva公司的加拿大品牌业务Vice President兼总经理（2014年7月至2016年9月）。Jacobs先生在主要制药公司担任范围越来越广、责任越来越大的职务，其中包括Cephalon Inc.（一家前公共生物制药和生物技术公司）、Wyeth，LLC（一家公共制药公司）和辉瑞公司（一家公共制药和生物技术公司）。Jacobs先生在纽约州立大学普拉茨堡学院（State University of New York College at Plattsburgh）获得商学学士学位，并在纽约州立大学宾厄姆顿分校（State University of New York at Binghamton）获得工商管理硕士学位。
- John C. Jacobs has served as our President and Chief Executive Officer and on our board of directors since June 2018. Previously, Mr. Jacobs served as our Executive Vice President and Chief Commercial Officer from October 2017 to June 2018. Prior to joining us, Mr. Jacobs served as the Senior Vice President and General Manager of the Respiratory Business Unit of Teva Pharmaceuticals Industries Ltd., or Teva, a public pharmaceutical company, from September 2017 to October 2017. He also served as Senior Vice President of Commercial Operations and Innovation of Teva, from September 2016 to September 2017 and as Vice President and General Manager of Teva’s Branded Business in Canada from July 2014 to September 2016. Mr. Jacobs has held positions of increasing scope and responsibility at major pharmaceutical companies including Cephalon Inc., a former public biopharmaceutical and biotechnology company, Wyeth, LLC, a public pharmaceutical company, and Pfizer Inc., a public pharmaceutical and biotechnology company. Mr. Jacobs received a B.S. in business from State University of New York College at Plattsburgh and an M.B.A. from The State University of New York at Binghamton.
- Antonio Gracias
-
Antonio Gracias自2017年9月起担任我们的董事会成员。自2001年9月以来，Gracias先生一直担任Valor Management LLC或Valor（一家私募股权公司）的首席执行官兼首席投资官。Gracias先生自2018年9月起担任Castle Creek Pharmaceuticals董事。他也曾担任Marathon Pharmaceuticals，LLC的董事（2013年11月至2017年5月被PTC Therapeutics收购），以及Solarcity Corporation（2012年至2016年）。Gracias先生自2007年5月起担任特斯拉公司董事会成员，包括2010年9月至2019年4月担任首席独立董事。Gracias先生还担任SpaceX的董事。Gracias先生在乔治敦大学外交学院获得国际金融和经济学学士/硕士顺丰控股S.学位，并在芝加哥大学法学院获得法学博士学位。
Antonio Gracias has served on our board of directors since September 2017. Since September 2001 Mr. Gracias has been Chief Executive Officer and Chief Investment Officer of Valor Management LLC, or Valor, a private equity firm. Mr. Gracias has served as a director of Castle Creek Pharmaceuticals since September 2018. He also served as a director of Marathon Pharmaceuticals, LLC from November 2013 until its acquisition by PTC Therapeutics in May 2017 and SolarCity Corporation from 2012 to 2016. Mr. Gracias has served on the board of directors of Tesla, Inc., since May 2007 including as Lead Independent Director from September 2010 to April 2019. Mr. Gracias also serves as director of SpaceX. Mr. Gracias received a joint B.S. / M.S.F.S. degree in international finance and economics from Georgetown University School of Foreign Service and a J.D. from the University of Chicago Law School. - Antonio Gracias自2017年9月起担任我们的董事会成员。自2001年9月以来，Gracias先生一直担任Valor Management LLC或Valor（一家私募股权公司）的首席执行官兼首席投资官。Gracias先生自2018年9月起担任Castle Creek Pharmaceuticals董事。他也曾担任Marathon Pharmaceuticals，LLC的董事（2013年11月至2017年5月被PTC Therapeutics收购），以及Solarcity Corporation（2012年至2016年）。Gracias先生自2007年5月起担任特斯拉公司董事会成员，包括2010年9月至2019年4月担任首席独立董事。Gracias先生还担任SpaceX的董事。Gracias先生在乔治敦大学外交学院获得国际金融和经济学学士/硕士顺丰控股S.学位，并在芝加哥大学法学院获得法学博士学位。
- Antonio Gracias has served on our board of directors since September 2017. Since September 2001 Mr. Gracias has been Chief Executive Officer and Chief Investment Officer of Valor Management LLC, or Valor, a private equity firm. Mr. Gracias has served as a director of Castle Creek Pharmaceuticals since September 2018. He also served as a director of Marathon Pharmaceuticals, LLC from November 2013 until its acquisition by PTC Therapeutics in May 2017 and SolarCity Corporation from 2012 to 2016. Mr. Gracias has served on the board of directors of Tesla, Inc., since May 2007 including as Lead Independent Director from September 2010 to April 2019. Mr. Gracias also serves as director of SpaceX. Mr. Gracias received a joint B.S. / M.S.F.S. degree in international finance and economics from Georgetown University School of Foreign Service and a J.D. from the University of Chicago Law School.
- Jack Bech Nielsen
-
Jack Bech Nielsen自2017年9月以来一直担任我们的董事会成员。尼尔森先生自2017年8月起担任专注于梦百合的投资公司Vivo Capital，LLC的董事总经理，并于2017年3月至2017年7月担任Vivo Capital的顾问。从2001年4月至2017年2月，尼尔森先生在Novo Holdings A/S风险活动中担任多个职位，最近担任高级合伙人。Nielsen先生自2006年6月以来一直担任Reata制药公司公司（一家公共制药公司）的董事。他自2018年8月起担任AligosTherapeutics，Inc.的董事，自2019年3月起担任MacuLogix，Inc.的董事，自2020年4月起担任ALX Oncology Limited的董事。尼尔森先生此前曾担任上市生物技术公司的董事会成员，包括Crinetics Pharmaceuticals，Inc.、Merus，N.V.、ApolloEndosurgery，Inc.和AkebiaTherapeutics，Inc.他也曾任职于几个私人生物技术和制药公司的董事会，包括Procept Biorobotics Co.、Kanyos Bio，Inc.、Unchained Labs，Inc.、Anokion Therapeutics、Alios Biopharma，Inc.和ProteinSimple，Inc.。Nielsen先生获得工商管理硕士学位。拥有丹麦技术大学化学工程学士学位和丹麦技术大学技术，经济和管理中心技术和经济管理硕士学位。
Jack Bech Nielsen has served on our board of directors since September 2017. Mr. Nielsen has served as a Managing Director at Vivo Capital, LLC, a healthcare-focused investment firm, since August 2017 and as a consultant at Vivo Capital from March 2017 to July 2017. From April 2001 to February 2017 Mr. Nielsen worked within the Novo Holdings A/S venture activities in several roles, most recently being employed as a Senior Partner. Mr. Nielsen has served on the board of directors of Reata Pharmaceuticals, Inc., a public pharmaceutical company, since June 2006. He has also served on the board of directors of Aligos Therapeutics, Inc. since August 2018 MacuLogix, Inc. since March 2019 and ALX Oncology Limited since April 2020. Mr. Nielsen previously served on the board of directors of public biotechnology companies including Crinetics Pharmaceuticals, Inc, Merus, N.V., Apollo Endosurgery, Inc. and Akebia Therapeutics, Inc. He also served on the board of directors of several private biotechnology and pharmaceutical companies including PROCEPT BioRobotics Co., Kanyos Bio, Inc., Unchained Labs, Inc., Anokion Therapeutics, Alios Biopharma, Inc. and ProteinSimple, Inc. Mr. Nielsen received a M.Sc. in chemical engineering from the Technical University of Denmark and a Masters in management of technology and economics from the Center for Technology, Economics and Management at the Technical University of Denmark. - Jack Bech Nielsen自2017年9月以来一直担任我们的董事会成员。尼尔森先生自2017年8月起担任专注于梦百合的投资公司Vivo Capital，LLC的董事总经理，并于2017年3月至2017年7月担任Vivo Capital的顾问。从2001年4月至2017年2月，尼尔森先生在Novo Holdings A/S风险活动中担任多个职位，最近担任高级合伙人。Nielsen先生自2006年6月以来一直担任Reata制药公司公司（一家公共制药公司）的董事。他自2018年8月起担任AligosTherapeutics，Inc.的董事，自2019年3月起担任MacuLogix，Inc.的董事，自2020年4月起担任ALX Oncology Limited的董事。尼尔森先生此前曾担任上市生物技术公司的董事会成员，包括Crinetics Pharmaceuticals，Inc.、Merus，N.V.、ApolloEndosurgery，Inc.和AkebiaTherapeutics，Inc.他也曾任职于几个私人生物技术和制药公司的董事会，包括Procept Biorobotics Co.、Kanyos Bio，Inc.、Unchained Labs，Inc.、Anokion Therapeutics、Alios Biopharma，Inc.和ProteinSimple，Inc.。Nielsen先生获得工商管理硕士学位。拥有丹麦技术大学化学工程学士学位和丹麦技术大学技术，经济和管理中心技术和经济管理硕士学位。
- Jack Bech Nielsen has served on our board of directors since September 2017. Mr. Nielsen has served as a Managing Director at Vivo Capital, LLC, a healthcare-focused investment firm, since August 2017 and as a consultant at Vivo Capital from March 2017 to July 2017. From April 2001 to February 2017 Mr. Nielsen worked within the Novo Holdings A/S venture activities in several roles, most recently being employed as a Senior Partner. Mr. Nielsen has served on the board of directors of Reata Pharmaceuticals, Inc., a public pharmaceutical company, since June 2006. He has also served on the board of directors of Aligos Therapeutics, Inc. since August 2018 MacuLogix, Inc. since March 2019 and ALX Oncology Limited since April 2020. Mr. Nielsen previously served on the board of directors of public biotechnology companies including Crinetics Pharmaceuticals, Inc, Merus, N.V., Apollo Endosurgery, Inc. and Akebia Therapeutics, Inc. He also served on the board of directors of several private biotechnology and pharmaceutical companies including PROCEPT BioRobotics Co., Kanyos Bio, Inc., Unchained Labs, Inc., Anokion Therapeutics, Alios Biopharma, Inc. and ProteinSimple, Inc. Mr. Nielsen received a M.Sc. in chemical engineering from the Technical University of Denmark and a Masters in management of technology and economics from the Center for Technology, Economics and Management at the Technical University of Denmark.
- Juan A. Sabater
-
Juan A.Sabater自2017年以来一直担任我们的董事会成员。Sabater自2010年起在Valor担任多个职位，最近担任总裁。加入Valor之前，Sabater从1998年到2006年担任Goldman Sachs&Co.投资银行部门总经理。他目前也任职于几个私人公司和组织的董事会，包括the Frick Collection and Girls Who Code Inc.。Sabater先生目前担任Augeo Affinity Marketing，Inc.的联合主席，也是休伊特学校（Hewitt School）的董事会成员。他在普林斯顿大学（Princeton University）获得历史学学士学位，在斯坦福大学法学院（Stanford Law School）获得法学博士学位。Sabater先生也曾是美国陆军预备役军官。
Juan A. Sabater has served on our board of directors since 2017. Mr. Sabater has served in various roles at Valor since 2010 most recently as President. Prior to joining Valor, Mr. Sabater was a Managing Director of Goldman Sachs & Co. in their Investment Banking Division, from 1998 to 2006. He also currently serves on the board of several private companies and organizations including The Frick Collection and Girls Who Code Inc. Mr. Sabater currently serves as the Co-Chairman of Augeo Affinity Marketing, Inc., and also sits on the board of trustees of The Hewitt School. He received an A.B. in history from Princeton University and a J.D. from Stanford Law School. Mr. Sabater was also a former officer in the U.S. Army Reserve. - Juan A.Sabater自2017年以来一直担任我们的董事会成员。Sabater自2010年起在Valor担任多个职位，最近担任总裁。加入Valor之前，Sabater从1998年到2006年担任Goldman Sachs&Co.投资银行部门总经理。他目前也任职于几个私人公司和组织的董事会，包括the Frick Collection and Girls Who Code Inc.。Sabater先生目前担任Augeo Affinity Marketing，Inc.的联合主席，也是休伊特学校（Hewitt School）的董事会成员。他在普林斯顿大学（Princeton University）获得历史学学士学位，在斯坦福大学法学院（Stanford Law School）获得法学博士学位。Sabater先生也曾是美国陆军预备役军官。
- Juan A. Sabater has served on our board of directors since 2017. Mr. Sabater has served in various roles at Valor since 2010 most recently as President. Prior to joining Valor, Mr. Sabater was a Managing Director of Goldman Sachs & Co. in their Investment Banking Division, from 1998 to 2006. He also currently serves on the board of several private companies and organizations including The Frick Collection and Girls Who Code Inc. Mr. Sabater currently serves as the Co-Chairman of Augeo Affinity Marketing, Inc., and also sits on the board of trustees of The Hewitt School. He received an A.B. in history from Princeton University and a J.D. from Stanford Law School. Mr. Sabater was also a former officer in the U.S. Army Reserve.
- Andreas Wicki
-
Andreas Wicki，在2006年12月公司成立时担任我们的董事。他是一名生命科学企业家和投资者，拥有20多年的制药和生物技术产业经验。他自2001年起是HBM Partners AG和HBM Healthcare Investments AG（前身是HBM BioVentures AG）的首席执行官。从1998年到2001年他是MDS股份有限公司European Analytical Operations的高级副总裁。从1990年到1998年他是ANAWA Laboratorien AG和Clinserve AG（两个签订合同的生命科学研究公司）共同拥有者和首席执行官。从2007年到2011年他是PharmaSwiss SA董事会的成员。先前，他在几家私人控股公司担任董事职位，并且公司在国际交易所上市。他拥有瑞士伯尔尼大学（the University of Bern, Switzerland）化学和生物化学硕士和博士学位。他目前在Buchler GmbH, HBM Healthcare Investments （Cayman） Ltd., HBM Partners Ltd和 HBM BioCapital Ltd董事会工作。
Andreas Wicki has served on our board of directors since September 2017. Dr. Wicki has served as Chief Executive Officer of HBM Healthcare Investments AG formerly HBM BioVentures AG since July 2001. From 1998 to 2001 Dr. Wicki was the Senior Vice President of the European Analytical Operations at MDS Inc. From 1990 to 1998 he was co-owner and Chief Executive Officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. Dr. Wicki currently serves on the board of directors of Pacira BioSciences, Inc., a public pharmaceutical company, Buchler GmbH, HBM Healthcare Investments (Cayman) Ltd., HBM BioCapital Ltd., Viela Bio, Inc., a public clinical-stage biotechnology company, and Vitaeris, Inc., a private clinical-stage biopharmaceutical company. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry from the University of Bern, Switzerland. - Andreas Wicki，在2006年12月公司成立时担任我们的董事。他是一名生命科学企业家和投资者，拥有20多年的制药和生物技术产业经验。他自2001年起是HBM Partners AG和HBM Healthcare Investments AG（前身是HBM BioVentures AG）的首席执行官。从1998年到2001年他是MDS股份有限公司European Analytical Operations的高级副总裁。从1990年到1998年他是ANAWA Laboratorien AG和Clinserve AG（两个签订合同的生命科学研究公司）共同拥有者和首席执行官。从2007年到2011年他是PharmaSwiss SA董事会的成员。先前，他在几家私人控股公司担任董事职位，并且公司在国际交易所上市。他拥有瑞士伯尔尼大学（the University of Bern, Switzerland）化学和生物化学硕士和博士学位。他目前在Buchler GmbH, HBM Healthcare Investments （Cayman） Ltd., HBM Partners Ltd和 HBM BioCapital Ltd董事会工作。
- Andreas Wicki has served on our board of directors since September 2017. Dr. Wicki has served as Chief Executive Officer of HBM Healthcare Investments AG formerly HBM BioVentures AG since July 2001. From 1998 to 2001 Dr. Wicki was the Senior Vice President of the European Analytical Operations at MDS Inc. From 1990 to 1998 he was co-owner and Chief Executive Officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. Dr. Wicki currently serves on the board of directors of Pacira BioSciences, Inc., a public pharmaceutical company, Buchler GmbH, HBM Healthcare Investments (Cayman) Ltd., HBM BioCapital Ltd., Viela Bio, Inc., a public clinical-stage biotechnology company, and Vitaeris, Inc., a private clinical-stage biopharmaceutical company. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry from the University of Bern, Switzerland.
- Jeffrey S. Aronin
-
Jeffrey S. Aronin，他现任Paragon制药公司董事长兼首席执行官，该公司是一家全球发展和生物制药投资公司。同时，他还是处方制药公司Marathon制药公司董事长兼首席执行官。2000年至2009年他曾任奥维森制药公司总裁兼首席执行官。奥维森制药公司是由他本人于2000年创立的一家生物制药公司，2009年被丹麦灵北制药公司收购。2009年丹麦灵北收购整合奥维森制药公司期间，他曾任丹麦灵北总裁兼首席执行官。他曾任MedCare技术公司董事长兼首席执行官，该公司为一家上市医疗保健公司。
Jeffrey S. Aronin,Founder, chairman and chief executive officer of Paragon Biosciences, LLC, an affiliated global life science innovation and investment firm.Established and is chairman of several of Paragon's portfolio companies - Harmony Biosciences (Nasdaq – HRMY), Castle Creek Biosciences, Emalex Biosciences, Evozyne and CIRC Biosciences since 2017.Previously served as CEO of several global biopharmaceutical companies focused on therapies for people with high unmet medical needs. - Jeffrey S. Aronin，他现任Paragon制药公司董事长兼首席执行官，该公司是一家全球发展和生物制药投资公司。同时，他还是处方制药公司Marathon制药公司董事长兼首席执行官。2000年至2009年他曾任奥维森制药公司总裁兼首席执行官。奥维森制药公司是由他本人于2000年创立的一家生物制药公司，2009年被丹麦灵北制药公司收购。2009年丹麦灵北收购整合奥维森制药公司期间，他曾任丹麦灵北总裁兼首席执行官。他曾任MedCare技术公司董事长兼首席执行官，该公司为一家上市医疗保健公司。
- Jeffrey S. Aronin,Founder, chairman and chief executive officer of Paragon Biosciences, LLC, an affiliated global life science innovation and investment firm.Established and is chairman of several of Paragon's portfolio companies - Harmony Biosciences (Nasdaq – HRMY), Castle Creek Biosciences, Emalex Biosciences, Evozyne and CIRC Biosciences since 2017.Previously served as CEO of several global biopharmaceutical companies focused on therapies for people with high unmet medical needs.
- Jack B. Nielsen
-
Jack B. Nielsen，自2006年10月起担任我们的董事。Nielsen先生自2001年起就在the Novo A/S organization及其风险活动方面任职，最近被聘为合伙人。2006年至2012年，Nielsen先生被Novo Ventures US Inc.聘为合伙人。1990年至2001年，他在Novo Nordisk（2000年成为Novozymes A/S）担任多个职位。Nielsen先生目前是Akebia Therapeutics, Inc., Alios BioPharma Inc., Apollo Endosurgery Inc., BioClin Therapeutics Inc., Reata Pharmaceuticals Inc.和Tobira Therapeutics Inc.的董事。 Nielsen先生于1990年获得了Technical University of Denmark的硕士学位，2000年获得哥本哈根the Center for Technology, Economics and Management的技术管理硕士学位。
Jack B. Nielsen has served as a member our board of directors since January 2021. Since August 2017 Mr. Nielsen has served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm and was recently promoted as a Managing Partner. Prior to March 2017 Mr. Nielsen worked within the Novo Holdings A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. Mr. Nielsen is currently a member of the board of directors of Aligos Therapeutics, Inc., Reata Pharmaceuticals, Inc., Harmony Biosciences, ALX Oncology Holdings Inc. and Instil Bio, Inc., all of which are publicly traded companies, and a number of private companies. Mr. Nielsen, in the past, has served on the boards of directors of Akebia Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is publicly traded. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology and Economics from the Center for Technology, Economics and Management, Technical University of Denmark. - Jack B. Nielsen，自2006年10月起担任我们的董事。Nielsen先生自2001年起就在the Novo A/S organization及其风险活动方面任职，最近被聘为合伙人。2006年至2012年，Nielsen先生被Novo Ventures US Inc.聘为合伙人。1990年至2001年，他在Novo Nordisk（2000年成为Novozymes A/S）担任多个职位。Nielsen先生目前是Akebia Therapeutics, Inc., Alios BioPharma Inc., Apollo Endosurgery Inc., BioClin Therapeutics Inc., Reata Pharmaceuticals Inc.和Tobira Therapeutics Inc.的董事。 Nielsen先生于1990年获得了Technical University of Denmark的硕士学位，2000年获得哥本哈根the Center for Technology, Economics and Management的技术管理硕士学位。
- Jack B. Nielsen has served as a member our board of directors since January 2021. Since August 2017 Mr. Nielsen has served as a Managing Director at Vivo Capital LLC, a healthcare focused investment firm and was recently promoted as a Managing Partner. Prior to March 2017 Mr. Nielsen worked within the Novo Holdings A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. Mr. Nielsen is currently a member of the board of directors of Aligos Therapeutics, Inc., Reata Pharmaceuticals, Inc., Harmony Biosciences, ALX Oncology Holdings Inc. and Instil Bio, Inc., all of which are publicly traded companies, and a number of private companies. Mr. Nielsen, in the past, has served on the boards of directors of Akebia Therapeutics, Inc., Crinetics Pharmaceuticals, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is publicly traded. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Masters in Management of Technology and Economics from the Center for Technology, Economics and Management, Technical University of Denmark.
高管简历
中英对照 | 中文 | 英文- John C. Jacobs
John C.Jacobs自2018年6月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。此前，Jacobs先生于2017年10月至2018年6月担任我们的执行Vice President兼首席商务官。在加入我们之前，Jacobs先生于2017年9月至2017年10月担任Teva Pharmaceuticals Industries Ltd.（或Teva，一家上市制药公司）呼吸业务部的高级副总裁兼总经理。他也曾担任Teva公司的商业运营和创新高级副总裁（2016年9月至2017年9月），以及Teva公司的加拿大品牌业务Vice President兼总经理（2014年7月至2016年9月）。Jacobs先生在主要制药公司担任范围越来越广、责任越来越大的职务，其中包括Cephalon Inc.（一家前公共生物制药和生物技术公司）、Wyeth，LLC（一家公共制药公司）和辉瑞公司（一家公共制药和生物技术公司）。Jacobs先生在纽约州立大学普拉茨堡学院（State University of New York College at Plattsburgh）获得商学学士学位，并在纽约州立大学宾厄姆顿分校（State University of New York at Binghamton）获得工商管理硕士学位。
John C. Jacobs has served as our President and Chief Executive Officer and on our board of directors since June 2018. Previously, Mr. Jacobs served as our Executive Vice President and Chief Commercial Officer from October 2017 to June 2018. Prior to joining us, Mr. Jacobs served as the Senior Vice President and General Manager of the Respiratory Business Unit of Teva Pharmaceuticals Industries Ltd., or Teva, a public pharmaceutical company, from September 2017 to October 2017. He also served as Senior Vice President of Commercial Operations and Innovation of Teva, from September 2016 to September 2017 and as Vice President and General Manager of Teva’s Branded Business in Canada from July 2014 to September 2016. Mr. Jacobs has held positions of increasing scope and responsibility at major pharmaceutical companies including Cephalon Inc., a former public biopharmaceutical and biotechnology company, Wyeth, LLC, a public pharmaceutical company, and Pfizer Inc., a public pharmaceutical and biotechnology company. Mr. Jacobs received a B.S. in business from State University of New York College at Plattsburgh and an M.B.A. from The State University of New York at Binghamton.- John C.Jacobs自2018年6月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。此前，Jacobs先生于2017年10月至2018年6月担任我们的执行Vice President兼首席商务官。在加入我们之前，Jacobs先生于2017年9月至2017年10月担任Teva Pharmaceuticals Industries Ltd.（或Teva，一家上市制药公司）呼吸业务部的高级副总裁兼总经理。他也曾担任Teva公司的商业运营和创新高级副总裁（2016年9月至2017年9月），以及Teva公司的加拿大品牌业务Vice President兼总经理（2014年7月至2016年9月）。Jacobs先生在主要制药公司担任范围越来越广、责任越来越大的职务，其中包括Cephalon Inc.（一家前公共生物制药和生物技术公司）、Wyeth，LLC（一家公共制药公司）和辉瑞公司（一家公共制药和生物技术公司）。Jacobs先生在纽约州立大学普拉茨堡学院（State University of New York College at Plattsburgh）获得商学学士学位，并在纽约州立大学宾厄姆顿分校（State University of New York at Binghamton）获得工商管理硕士学位。
- John C. Jacobs has served as our President and Chief Executive Officer and on our board of directors since June 2018. Previously, Mr. Jacobs served as our Executive Vice President and Chief Commercial Officer from October 2017 to June 2018. Prior to joining us, Mr. Jacobs served as the Senior Vice President and General Manager of the Respiratory Business Unit of Teva Pharmaceuticals Industries Ltd., or Teva, a public pharmaceutical company, from September 2017 to October 2017. He also served as Senior Vice President of Commercial Operations and Innovation of Teva, from September 2016 to September 2017 and as Vice President and General Manager of Teva’s Branded Business in Canada from July 2014 to September 2016. Mr. Jacobs has held positions of increasing scope and responsibility at major pharmaceutical companies including Cephalon Inc., a former public biopharmaceutical and biotechnology company, Wyeth, LLC, a public pharmaceutical company, and Pfizer Inc., a public pharmaceutical and biotechnology company. Mr. Jacobs received a B.S. in business from State University of New York College at Plattsburgh and an M.B.A. from The State University of New York at Binghamton.
- Susan L. Drexler
Susan L.Drexler自2019年10月起担任我们的首席财务官。从2018年4月至2019年6月，德雷克斯勒女士担任Ocugen，Inc.业务发展临时首席财务官兼Vice President2015年8月至2017年11月，德雷克斯勒女士在美源伯根公司担任业务开发和市场情报方面的高级职位。从2007年7月到2015年6月，Drexler女士在Shire Pharmaceuticals担任高级开发财务职位。在她职业生涯的早期，Drexler女士在Duff&Phelps，LLC担任财务咨询职责递增的职位，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）担任高级审计职位。Drexler女士在奥尔布赖特学院（Albright College）获得会计学学士学位，并在匹兹堡大学（University of Pittsburgh）约瑟夫·卡茨商学院（Joseph M.Katz Graduate School of Business）获得工商管理硕士学位。Drexler女士是宾夕法尼亚州的注册会计师。
Susan L. Drexler,has served as Aileron Therapeutics, Inc. interim chief financial officer since June 2022. Since January 2022, Ms. Drexler has served as a chief financial officer consultant at Danforth Advisors, a firm that specializes in outsourced corporate functions for life sciences companies. From October 2019 to March 2021, Ms. Drexler served as chief financial officer at Harmony Biosciences, a life sciences company. From April 2018 to June 2019, Ms. Drexler served in various roles as interim chief financial officer and vice president of business development at Ocugen, Inc., a biotechnology company. From August 2015 to November 2017, Ms. Drexler served in senior roles in business development and market intelligence at AmerisourceBergen Corporation, a company that provides distribution, logistics and technology solutions to life sciences companies. From July 2007 to June 2015, Ms. Drexler held a senior business development finance role at Shire Pharmaceuticals, a biopharmaceutical company. Earlier in her career, Ms. Drexler held roles of increasing responsibility in finance consulting at Duff & Phelps, LLC, a financial consultancy firm, and senior audit roles at PricewaterhouseCoopers. Ms. Drexler earned a B.S. in Accounting from Albright College and an M.B.A. from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Ms. Drexler is a Certified Public Accountant in the State of Pennsylvania.- Susan L.Drexler自2019年10月起担任我们的首席财务官。从2018年4月至2019年6月，德雷克斯勒女士担任Ocugen，Inc.业务发展临时首席财务官兼Vice President2015年8月至2017年11月，德雷克斯勒女士在美源伯根公司担任业务开发和市场情报方面的高级职位。从2007年7月到2015年6月，Drexler女士在Shire Pharmaceuticals担任高级开发财务职位。在她职业生涯的早期，Drexler女士在Duff&Phelps，LLC担任财务咨询职责递增的职位，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）担任高级审计职位。Drexler女士在奥尔布赖特学院（Albright College）获得会计学学士学位，并在匹兹堡大学（University of Pittsburgh）约瑟夫·卡茨商学院（Joseph M.Katz Graduate School of Business）获得工商管理硕士学位。Drexler女士是宾夕法尼亚州的注册会计师。
- Susan L. Drexler,has served as Aileron Therapeutics, Inc. interim chief financial officer since June 2022. Since January 2022, Ms. Drexler has served as a chief financial officer consultant at Danforth Advisors, a firm that specializes in outsourced corporate functions for life sciences companies. From October 2019 to March 2021, Ms. Drexler served as chief financial officer at Harmony Biosciences, a life sciences company. From April 2018 to June 2019, Ms. Drexler served in various roles as interim chief financial officer and vice president of business development at Ocugen, Inc., a biotechnology company. From August 2015 to November 2017, Ms. Drexler served in senior roles in business development and market intelligence at AmerisourceBergen Corporation, a company that provides distribution, logistics and technology solutions to life sciences companies. From July 2007 to June 2015, Ms. Drexler held a senior business development finance role at Shire Pharmaceuticals, a biopharmaceutical company. Earlier in her career, Ms. Drexler held roles of increasing responsibility in finance consulting at Duff & Phelps, LLC, a financial consultancy firm, and senior audit roles at PricewaterhouseCoopers. Ms. Drexler earned a B.S. in Accounting from Albright College and an M.B.A. from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Ms. Drexler is a Certified Public Accountant in the State of Pennsylvania.
- Jeffrey Dayno
Jeffrey Dayno自2017年11月起担任我们的首席医疗官。Dayno博士还于2014年7月至2017年10月担任Eaglet Co.（现称为Zyla Life Sciences）的首席医疗官。在加入Eaglet Co.之前，Dayno博士从2011年8月到2014年1月担任ViroPharma，Inc.全球医疗事务Vice President，当时该公司被Shire Pharmaceuticals收购。Dayno博士自2016年3月起担任ATRIN Pharmaceuticals，LLC（一家私人生物制药公司）的董事会成员。Dayno博士在坦普尔大学医院（Temple University Hospital）完成了神经病学住院医师学位，然后在密歇根州底特律的亨利福特医院（Henry Ford Hospital）完成了中风和脑血管疾病的研究金，这是美国国家卫生研究院（National Institutes of Health）中风项目赠款的一部分。他是创始成员之一，并担任费城中风委员会（Philadelphia Stroke Council）的董事会主席，这是一个非营利组织，致力于患者意识和专业教育，以推进向急性中风治疗的努力。Dayno自2013年3月起担任Temple University School of Medicine访客委员会成员。Dayno博士在三一学院（Trinity College）获得国际研究学士学位，并在坦普尔大学医学院（Temple University School of Medicine）获得医学博士学位。
Jeffrey Dayno has served as our Chief Medical Officer since November 2017. Dr. Dayno also served as Chief Medical Officer of Eaglet Co., now known as Zyla Life Sciences, from July 2014 to October 2017. Prior to joining Eaglet Co., Dr. Dayno served as Vice President of Global Medical Affairs at ViroPharma, Inc., from August 2011 to January 2014 at which time it was acquired by Shire Pharmaceuticals. Since March 2016 Dr. Dayno has served on the board of directors of Atrin Pharmaceuticals, LLC, a private biopharmaceutical company. Dr. Dayno completed his residency in neurology at Temple University Hospital then completed a fellowship in stroke and cerebrovascular diseases at Henry Ford Hospital in Detroit, Michigan, as part of a National Institutes of Health program grant in stroke. He was one of the founding members and served as the Chairman of the Board of the Philadelphia Stroke Council, a non-profit organization dedicated to patient awareness and professional education to advance the efforts toward acute stroke treatment. Since March 2013 Dr. Dayno has been a member of the board of visitors of Temple University School of Medicine. Dr. Dayno received a B.A. in international studies from Trinity College and an M.D. from Temple University School of Medicine.- Jeffrey Dayno自2017年11月起担任我们的首席医疗官。Dayno博士还于2014年7月至2017年10月担任Eaglet Co.（现称为Zyla Life Sciences）的首席医疗官。在加入Eaglet Co.之前，Dayno博士从2011年8月到2014年1月担任ViroPharma，Inc.全球医疗事务Vice President，当时该公司被Shire Pharmaceuticals收购。Dayno博士自2016年3月起担任ATRIN Pharmaceuticals，LLC（一家私人生物制药公司）的董事会成员。Dayno博士在坦普尔大学医院（Temple University Hospital）完成了神经病学住院医师学位，然后在密歇根州底特律的亨利福特医院（Henry Ford Hospital）完成了中风和脑血管疾病的研究金，这是美国国家卫生研究院（National Institutes of Health）中风项目赠款的一部分。他是创始成员之一，并担任费城中风委员会（Philadelphia Stroke Council）的董事会主席，这是一个非营利组织，致力于患者意识和专业教育，以推进向急性中风治疗的努力。Dayno自2013年3月起担任Temple University School of Medicine访客委员会成员。Dayno博士在三一学院（Trinity College）获得国际研究学士学位，并在坦普尔大学医学院（Temple University School of Medicine）获得医学博士学位。
- Jeffrey Dayno has served as our Chief Medical Officer since November 2017. Dr. Dayno also served as Chief Medical Officer of Eaglet Co., now known as Zyla Life Sciences, from July 2014 to October 2017. Prior to joining Eaglet Co., Dr. Dayno served as Vice President of Global Medical Affairs at ViroPharma, Inc., from August 2011 to January 2014 at which time it was acquired by Shire Pharmaceuticals. Since March 2016 Dr. Dayno has served on the board of directors of Atrin Pharmaceuticals, LLC, a private biopharmaceutical company. Dr. Dayno completed his residency in neurology at Temple University Hospital then completed a fellowship in stroke and cerebrovascular diseases at Henry Ford Hospital in Detroit, Michigan, as part of a National Institutes of Health program grant in stroke. He was one of the founding members and served as the Chairman of the Board of the Philadelphia Stroke Council, a non-profit organization dedicated to patient awareness and professional education to advance the efforts toward acute stroke treatment. Since March 2013 Dr. Dayno has been a member of the board of visitors of Temple University School of Medicine. Dr. Dayno received a B.A. in international studies from Trinity College and an M.D. from Temple University School of Medicine.
- Jeffrey Dierks
Jeffrey Dierks自2018年7月起担任我们的首席商务官。在担任首席商务官之前，Dierks先生于2017年10月至2018年7月担任我们的营销Vice President。在加入Harmony之前，Dierks先生于2014年6月至2016年12月在Teva Pharmaceuticals担任高级营销职位，领导美国疼痛护理和清醒投资组合，并于2016年12月至2017年10月在美国偏头痛营销。在加入Teva之前，Dierks先生在几家主要制药公司担任越来越重要的商业角色，包括Janssen Pharmaceuticals Inc.，Endo Pharmaceuticals和Wyeth Pharmaceuticals。2017年，PM360杂志授予Dierks先生制药行业变革领导者的荣誉，并于2010年获得开拓者奖。Dierks先生在西马里兰学院（Western Maryland College）获得政治学学士学位，并在坦普尔大学福克斯商学院（Temple University&8217；s Fox School of Business）获得营销学工商管理硕士学位。
Jeffrey Dierks has served as our Chief Commercial Officer since July 2018. Prior to his role as Chief Commercial Officer, Mr. Dierks served as our Vice President of Marketing from October 2017 to July 2018. Prior to joining Harmony, Mr. Dierks served in senior marketing roles leading the U.S. Pain Care & Wakefulness portfolio from June 2014 to December 2016 and U.S. Migraine Marketing from December 2016 to October 2017 at Teva Pharmaceuticals. Before joining Teva, Mr. Dierks held commercial roles of increasing responsibility at several major pharmaceutical companies, including Janssen Pharmaceuticals Inc., Endo Pharmaceuticals and Wyeth Pharmaceuticals. In 2017 PM360 magazine honored Mr. Dierks as a transformational leader in the pharmaceutical industry and in 2010 with the Trailblazer Award. Mr. Dierks received a B.A. in political science from Western Maryland College and an M.B.A. in marketing from Temple University’s Fox School of Business.- Jeffrey Dierks自2018年7月起担任我们的首席商务官。在担任首席商务官之前，Dierks先生于2017年10月至2018年7月担任我们的营销Vice President。在加入Harmony之前，Dierks先生于2014年6月至2016年12月在Teva Pharmaceuticals担任高级营销职位，领导美国疼痛护理和清醒投资组合，并于2016年12月至2017年10月在美国偏头痛营销。在加入Teva之前，Dierks先生在几家主要制药公司担任越来越重要的商业角色，包括Janssen Pharmaceuticals Inc.，Endo Pharmaceuticals和Wyeth Pharmaceuticals。2017年，PM360杂志授予Dierks先生制药行业变革领导者的荣誉，并于2010年获得开拓者奖。Dierks先生在西马里兰学院（Western Maryland College）获得政治学学士学位，并在坦普尔大学福克斯商学院（Temple University&8217；s Fox School of Business）获得营销学工商管理硕士学位。
- Jeffrey Dierks has served as our Chief Commercial Officer since July 2018. Prior to his role as Chief Commercial Officer, Mr. Dierks served as our Vice President of Marketing from October 2017 to July 2018. Prior to joining Harmony, Mr. Dierks served in senior marketing roles leading the U.S. Pain Care & Wakefulness portfolio from June 2014 to December 2016 and U.S. Migraine Marketing from December 2016 to October 2017 at Teva Pharmaceuticals. Before joining Teva, Mr. Dierks held commercial roles of increasing responsibility at several major pharmaceutical companies, including Janssen Pharmaceuticals Inc., Endo Pharmaceuticals and Wyeth Pharmaceuticals. In 2017 PM360 magazine honored Mr. Dierks as a transformational leader in the pharmaceutical industry and in 2010 with the Trailblazer Award. Mr. Dierks received a B.A. in political science from Western Maryland College and an M.B.A. in marketing from Temple University’s Fox School of Business.
- Andrew Serafin
Andrew Serafin自2018年12月起担任我们的首席商务官。Serafin先生曾于2017年9月至2018年12月担任我们的业务发展和公司战略高级副总裁。此前，塞拉芬曾于2015年8月至2017年5月担任私人发展阶段生物制药公司Marathon Pharmaceuticals，LLC业务发展Vice President。他还于2015年4月至2015年8月担任私人制药公司Altathera Pharmaceuticals，LLC的业务发展and General Counsel Vice President，并于2006年7月至2015年3月担任Lundbeck Inc.（或Lundbeck）的交易整合Vice President兼副总法律顾问。任职公司期间，他也曾担任Lundbeck公司的代理总法律顾问6个月。他在伊利诺伊大学香槟分校（University of Illinois at Urbana-Champaign）获得金融学学士学位，在洛约拉大学芝加哥法学院（Loyola University Chicago School of Law）获得法学博士学位，在西北大学凯洛格管理学院（Northwestern University Kellogg School of Management）获得工商管理硕士学位。
Andrew Serafin has served as our Chief Business Officer since December 2018. Mr. Serafin previously served as our Senior Vice President of Business Development and Corporate Strategy from September 2017 to December 2018. Previously, Mr. Serafin served as the Vice President of Business Development at Marathon Pharmaceuticals, LLC, a private development-stage biopharmaceutical company, from August 2015 to May 2017. He also served as the Vice President of Business Development and General Counsel of AltaThera Pharmaceuticals, LLC, a private pharmaceutical company, from April 2015 to August 2015 and the Vice President of Deal Integration and Associate General Counsel of Lundbeck Inc., or Lundbeck, from July 2006 to March 2015. He also served as acting General Counsel of Lundbeck for six months during his time with the company. He received a B.S. in finance from University of Illinois at Urbana-Champaign, a J.D. from Loyola University Chicago School of Law and an M.B.A. from Northwestern University Kellogg School of Management.- Andrew Serafin自2018年12月起担任我们的首席商务官。Serafin先生曾于2017年9月至2018年12月担任我们的业务发展和公司战略高级副总裁。此前，塞拉芬曾于2015年8月至2017年5月担任私人发展阶段生物制药公司Marathon Pharmaceuticals，LLC业务发展Vice President。他还于2015年4月至2015年8月担任私人制药公司Altathera Pharmaceuticals，LLC的业务发展and General Counsel Vice President，并于2006年7月至2015年3月担任Lundbeck Inc.（或Lundbeck）的交易整合Vice President兼副总法律顾问。任职公司期间，他也曾担任Lundbeck公司的代理总法律顾问6个月。他在伊利诺伊大学香槟分校（University of Illinois at Urbana-Champaign）获得金融学学士学位，在洛约拉大学芝加哥法学院（Loyola University Chicago School of Law）获得法学博士学位，在西北大学凯洛格管理学院（Northwestern University Kellogg School of Management）获得工商管理硕士学位。
- Andrew Serafin has served as our Chief Business Officer since December 2018. Mr. Serafin previously served as our Senior Vice President of Business Development and Corporate Strategy from September 2017 to December 2018. Previously, Mr. Serafin served as the Vice President of Business Development at Marathon Pharmaceuticals, LLC, a private development-stage biopharmaceutical company, from August 2015 to May 2017. He also served as the Vice President of Business Development and General Counsel of AltaThera Pharmaceuticals, LLC, a private pharmaceutical company, from April 2015 to August 2015 and the Vice President of Deal Integration and Associate General Counsel of Lundbeck Inc., or Lundbeck, from July 2006 to March 2015. He also served as acting General Counsel of Lundbeck for six months during his time with the company. He received a B.S. in finance from University of Illinois at Urbana-Champaign, a J.D. from Loyola University Chicago School of Law and an M.B.A. from Northwestern University Kellogg School of Management.